Connection
Amrut Ambardekar to Natriuretic Peptide, Brain
This is a "connection" page, showing publications Amrut Ambardekar has written about Natriuretic Peptide, Brain.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.110 |
|
|
|
-
Fontana M, Ambardekar AV, Cappelli F, Cuddy SAM, Davis MK, Garcia-Pavia P, Hanna M, Khouri MG, Masri A, Maurer MS, Obici L, Solomon S, Sperry BW, Tahara N, Waddington-Cruz M, Conrad T, Yang Q, Chen J, Tsimikas S, Gillmore JD. Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. Eur J Heart Fail. 2026 Oct 28; 28(4):807-818.
Score: 0.058
-
Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, García-Pavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 04; 151(9):601-611.
Score: 0.051
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|